Ca-4-methyl-2-oxo-valerate (α-ketoanalogue to leucine, Ca salt) 101 mg, Ca-3-methyl-2-oxo-butyrate (α-ketoanalogue to valine, Ca salt) 86 mg, Ca-2-oxo-3-phenylpropionate (α-ketoanalogue to phenylalanine, Ca salt) 68 mg, Ca-3-methyl-2-oxo-valerate (α-ketoanalogue to isoleucine, Ca salt) 67 mg, Ca-DL-2-hydroxy-4-(methylthio) butyrate (α-ketoanalogue to methionine, Ca salt) 59 mg, L-lysine acetate 105 mg, L-threonine 53 mg, L-histidine 38 mg, L-tyrosine 30 mg, L-tryptophan 23 mg, total nitrogen content 36 mg, Ca 0.05 g (1.25 mmol)
Indications/Uses
Prevention & therapy of damages due to faulty or deficient protein metabolism in chronic renal insufficiency in connection w/ limited protein food of ≤40 g/day (for adults) & patients w/ GFR <25 mL/min.
Reduce vit D intake if hypercalcaemia occurs; dose & intake of any other Ca sources in case of persisting hypercalcaemia. Monitor decrease of serum phosphate levels. Pregnancy & lactation. No experience in childn.
May cause or aggravate elevated serum Ca levels w/ Ca-containing drugs. Risk of disturbed absorption w/ drugs forming hardly soluble compd w/ Ca (eg, tetracyclines, quinolones eg, ciprofloxacin & norfloxacin as well as drugs containing Fe, fluoride or estramustine). Increased risk of arrhythmia w/ cardioactive glycosides in the presence of hypercalcemia. Possible interaction w/ Al HCl.
Sign Out
